Orexo announces FDA acceptance of New Drug Application filing for OX124, a high-dose rescue medication for opioid overdose

Orexo Sweden

OX124 is based on Orexo´s world-class drug delivery platform, amorphOX®, and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanylSynthetic opioids are behind 91 percent of all fatal opioid overdoses in the US[1]Prescription Drug User Fee Act date (PDUFA) set to July 15, 2024. If approved, US launch is expected to be initiated late 2024.View original content:https://www.prnewswire.co.uk/news-releases/orexo-announces-fda-acceptance-of-new-drug-application-filing-for-ox124-a-high-dose-rescue-medication-for-opioid-overdose-301998807.html